iabetes mellitus (DM) adds incremental risk of the development and subsequent exacerbation of heart failure even after adjusting for common risk factors, such as ischemic heart disease and hypertension.
D
DM probably impairs cardiac function and causes additional myocardial damage. [2] [3] [4] [5] In addition, accelerated coronary atherosclerosis is likely to play a role. 6 Moreover, the choice of antihyperglycemic agents in those patients with DM with heart failure or at risk of developing it remains challenging. Some agents, such as thiazolidinediones and dual peroxisome proliferator-activated receptor α/γ agonists, increase plasma volume and exacerbate heart failure, [7] [8] [9] [10] [11] whereas sulfonylureas 12 and insulin potentially exacerbate the dysregulation of myocardial metabolism and worsen left ventricular function. 13, 14 Metformin, once felt to be contraindicated in patients with heart failure, is now considered to be 1 of the safest options, despite the absence of large randomized comparisons. 15, 16 Despite the observational relationship between glycemic control and the risk of heart failure, there is no evidence that improved glycemic control modifies this risk. 17 Therefore, identification of antihyperglycemic agents that can be used safely in patients with heart failure or at risk of developing heart failure remains an important unmet clinical need.
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Saxagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor. 18 The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial was designed to evaluate the long-term cardiovascular efficacy and safety of saxagliptin in patients with DM at risk of cardiovascular events. 19 Over a median of 2.1 years follow-up, saxagliptin neither increased nor decreased the risk of the primary or secondary composite end points; however, there was an unexpected 27% increased relative risk (and 0.7% absolute risk over 2 years) of hospitalization for heart failure in patients assigned to saxagliptin. 20 This report explores further the observation surrounding hospitalizations for heart failure by examining baseline risk factors associated with an increased risk of hospitalizations for heart failure, the timing of hospitalizations and the risk of recurrent events, and the association between baseline levels of natriuretic peptides and future hospitalizations for heart failure events.
Methods

Study Design and Oversight
As described previously, 19 the SAVOR-TIMI 53 trial was a multicenter, randomized, double-blind, placebo-controlled trial that randomized 16 492 patients at 788 sites in 26 countries from May 2010 to December 2011 with type 2 DM, hemoglobin A1c between 6.5% and <12.0% within 6 months of randomization, and either a history of established cardiovascular disease or multiple risk factors for vascular disease to receive either 5 mg of saxagliptin daily (or 2.5 mg daily in patients with an estimated glomerular filtration rate [eGFR] of ≤50 mL/min) or matching placebo. The full eligibility criteria and analysis plan have been reported previously. 19, 20 Written informed consent was obtained from all patients. The relevant ethics committees at all participating centers approved the protocol.
End Points
A clinical events committee, unaware of the study-group assignments, adjudicated all components of the primary and secondary composite efficacy end points. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke.
The secondary end point included the primary composite end point together with hospitalization for heart failure, coronary revascularization, or unstable angina. Heart failure requiring hospitalization was defined as an event that required hospitalization to an inpatient unit or a visit to an emergency department that resulted in at least a 12 hour stay with clinical manifestations of heart failure, including ≥1 of the following signs or symptoms: new or worsening dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, pulmonary basilar crackles, jugular venous distension, new or worsening third heart sound or gallop rhythm, or radiological evidence of worsening heart failure, together with additional or increased therapy that included initiation of intravenous diuretic, inotropic, or vasodilator therapy, uptitration of intravenous therapy, if already on therapy, initiation of mechanical or surgical support/intervention, or the use of ultrafiltration, hemofiltration, or dialysis that is specifically directed at treatment of heart failure. 19, 20 The end point definitions were developed to be consistent with the draft Standardized Definitions for End Point Events in Cardiovascular Trials created by an initiative from the Food and Drug Administration. 21 History of previous heart failure was a predefined subgroup based on medical history obtained at randomization.
N-terminal pro-B type natriuretic peptide (NT-proBNP) was measured in 12 301 patients (74.6% of the overall trial) at randomization and in a randomly selected subset of patients at 2 years or the end of treatment, whichever was earlier. Blood samples were collected in serum separator plastic tubes and then centrifuged and stored frozen in aliquots at −20° to −80°C at the enrolling site until shipped to the Biomarker Research/TIMI Clinical Trials Laboratory (Boston, MA), where they were maintained at −80°C. Serum NT-proBNP concentrations were measured at the first thaw using a sandwich immunoassay (proBNP II; Roche Diagnostics, Indianapolis, IN). The analytic range extends from 5 to 35 000 pg/mL. The reported within-run coefficient of variation was 4.2% at a level of 44 pg/mL and 2.7% at a level of 33 606 pg/mL. Plasma high-sensitivity troponin T was measured with an electrochemiluminescent immunoassay assay (Roche Diagnostics). The lower limit of detection of the assay is 0.003 μg/L.
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Statistical Analysis
All analyses were conducted on an intention-to-treat basis among patients who underwent randomization. Categorical variables were compared using χ 2 tests and continuous variable with either a t test or Wilcoxon rank-sum test, as appropriate. Events rates are presented as 2-year Kaplan-Meier estimates. The relative risks of hospitalization for heart failure between saxagliptin and placebo were examined using an unadjusted Cox proportional hazards model stratified by baseline renal impairment category and baseline cardiovascular risk group and with treatment as a model term. A post hoc Bonferroni correction was applied for the multiple comparisons of each composite of the secondary end point (n=6), providing a P value of 0.0083 for the comparison of saxagliptin versus placebo. Recurrent events analyses accounted for multiple hospitalizations for heart failure under a counting process assumption based on the method described by Anderson and Gill. 23 The risk of rehospitalization for heart failure after an initial hospitalization for heart failure was examined using the Prentice-Williams-Peterson Gap Time model. 24 Multivariable modeling for the risk of hospitalization for heart failure in the overall population was developed by first examining univariate associations and then with the backward elimination method to reduce the pool of covariates base on a P value of <0.05. It was refined further to include clinically meaningful covariates in the final model. The hazard ratio (HR) and 95% confidence interval (CI) were reported from landmark analyses based on subject-level censoring at 6 and 12 months that excluded subjects who did not have enough follow-up time or experienced the event before the landmarked time. A time-varying coefficient model was fitted as described by Gray 25 to evaluate any heterogeneity between saxagliptin and heart failure over time. treatment groups. A substantial proportion of patients hospitalized for heart failure, regardless of the treatment assignment, were subsequently readmitted for recurrent heart failure episodes (n=137, 26.5%) or died (n=135, 26.1%), mostly as a result of cardiovascular causes (n=121, 89.6% of deaths).
A comparison of the baseline variables in the patients hospitalized for heart failure compared with those who were not are shown in Table 1 . The former were older, more likely to be men, and have a history of heart failure, chronic kidney disease, established cardiovascular disease, including previous myocardial infarction, or coronary revascularization. In addition, they were more likely to be treated with aspirin, β-blockers, diuretics, statins, inhibitors of the renin-angiotensin system, and insulin and less likely to be treated with metformin, sulfonylureas, or thiazolidinediones.
Risk Factors for Hospitalization for Heart Failure in the Overall Population
Unadjusted HRs for the risk of hospitalization for heart failure by baseline characteristics are presented in Table 1 . In multivariable analysis, the strongest association with hospitalization for heart failure (as assessed by χ 2 test) regardless of treatment assignment was previous heart failure and 2 markers of renal disease, eGFR and the albumin/creatinine ratio ( Table 2 ). There was a stepwise increase in the risk of hospitalization for heart failure in patients who had 0, 1, or 2 of the risk factors of history of heart failure or an eGFR ≤60 m/min: 1.2% with 0 risk factors (n=10 418, 63.2%) (referent), 5.3% with 1 risk factor (n=5188, 31.5%; HR, 4.48; 95% CI, P<0.001) , and 14.3% with 2 risk factors (n=886, 5.4%; HR, 13.51; 95% CI, P<0.001) . When randomization is added to this model, the risk associated with saxagliptin was consistent with the overall trial (HR, 1.29; 95% CI, 1.08-1.54). The c-statistic for the model with eGFR and previous heart failure alone was 0.74, which increased to 0.81 with the addition of all clinical variables in Table 2 .
Saxagliptin and Hospitalization for Heart Failure
Over 2 years of follow-up, more patients in the saxagliptin group (289 of 8280, 3.5%) were hospitalized for heart failure compared with the placebo group (228 of 8212, 2.8%; HR, 1.27; 95% CI, 1.07-1.51; P=0.007). The corresponding rates at 6 months were 1.1% versus 0.6% (HR, 1.80; 95% CI, 1.29-2.55; P=0.001) and 1.9% versus 1.3% (HR, 1.46; 95% CI, 1.15-1.88; P=0.002) at 12 months (Figure 1 ). The rates for hospitalization for heart failure based on "investigator" reported events were consistent with the adjudicated results (see online-only Data Supplement Table I) .
Based on landmark analysis beginning at 6 and 12 months, the risk of hospitalization for heart failure after patients were assigned to saxagliptin was similar to placebo (2.4% versus 2.1%; HR, 1.11; 95% CI, ; P=0.31 beginning at 6 months; and 1.7% versus 1.5%; HR, 1.09; 95% CI, 0.85-1.39; P=0.51 at 12 months). To examine the attenuating effects of saxagliptin on the risk of hospitalization as a result of heart failure over time, a time-varying coefficients model was developed (P value for a time-time varying interaction term = 0.017). The lower CI of the log HR crosses 0 at ?314 days, suggesting that the risk of hospitalization for heart failure with saxagliptin subsided at 10 to 11 months after randomization (see online-only Data Supplement Figure I ). When the landmark analyses were restricted to patients taking the study drug, the corresponding risks were similar to the intent-to-treat analysis: from randomization to 12 months (HR, 1.52; 95% CI, 1.17-1.96; P=0.0015) and from 12 months onward (HR, 1.05; 95% CI, P=0.73) .
When analyzing both first and recurrent events combined, 413 total events occurred in the saxagliptin group compared with 328 events in the placebo group (HR, 1.26; 95% CI, 1.02-1.55; P=0.04). The risks for rehospitalizations for heart failure after an initial hospitalization for heart failure were similar in both groups (hospitalization for heart failure: 80, 27.7% saxagliptin versus 57, 25.0% for placebo; HR, 1.06; 95% CI, P=0.73; and mortality: 26.3% versus 25.9% placebo; HR, 1.01; 95% CI, P=0.95) . The median length of stay for the initial adjudicated hospitalization for heart failure was 7.0 days in both treatment groups. The most common treatment was intravenous diuretics (88% in each group). Vasodilator therapy was used in 6.2% for saxagliptin subjects and in 7.9% for placebo subjects. Ultrafiltration/hemodialysis (2.8% and 2.2% for saxagliptin and placebo, respectively) and advanced hemodynamic support (1.7% and 0.9% for saxagliptin and placebo, respectively) were used infrequently.
At 1 year, weights were similar in the overall saxagliptin and placebo groups (87.6±18.4 versus 87.9±19.4 kg; P=0.87) and in patients with a history of heart failure (91.5±19.5 versus 92.8±20.5 kg; P=0.27) or eGFR ≤60 mL/min (87.1±18.8 versus 87.9±19.7 kg; P=0.47). Treatment with saxagliptin did not result in clinically detectable fluid overload as reflected by similar rates of adverse event reports of edema (45 for saxagliptin versus 46 for placebo) and peripheral edema (347 for saxagliptin versus 352 for placebo).
Although the absolute rate of hospitalization for heart failure varied considerably among the predefined subgroups and in patients with and without previous heart failure, the relative risk in patients treated with saxagliptin was similar across subgroups (see online-only Data Supplement Figure II) . Consequently, the absolute rates of heart failure difference between saxagliptin and placebo varied according to the overall risk within each subgroup. This pattern was reinforced when examining the relative and absolute risk differences in patients with the 2 clinical risk factors that most greatly increased the risk of hospitalization for heart failure, eGFR ≤60 mL/min and a previous history of heart failure ( Figure 2 ). For example, in patients with neither of these risk factors, the absolute risk difference over 2 years between saxagliptin and placebo was 0.3% compared with 1.7% in patients with both risk factors. The number of excess hospitalizations for heart failure per year if 1000 patients were treated with saxagliptin ranged from 0 in patients with no risk factors to 8 in patients with both risk factors.
Baseline NT-proBNP and Heart Failure
The median NT-proBNP in the 12 301 patients in whom it was measured at baseline was 141 pg/mL (interquartile ratio, 64-332), and it was similar in patients assigned to saxagliptin (143 pg/mL; interquartile ratio, 65-336) and placebo (139 pg/mL; interquartile ratio, 63-330). There was a stepwise increased risk of hospitalization for heart failure with higher quartiles of baseline NT-proBNP ( Figure 3 ). When added to Table II ).
The c-statistic increased from 0.81 to 0.85 (P<0.001) when NT-proBNP was added to the clinical variables in Table 2 . In the cohort with the highest quartile of NT-proBNP, the risk of hospitalization for heart failure in patients treated with saxagliptin was similar to that observed in the overall trial (HR, 1.31; 95% CI, 1.04-1.66; P=0.02). Although there was no evidence of heterogeneity between levels of NT-proBNP, treatment with saxagliptin, and hospitalization for heart failure (P for interaction=0.46), the absolute risk excess for heart failure with saxagliptin was greatest in the highest NT-proBNP quartile (2.1%) compared with quartiles 1 (0.0%), 2 (0.7%), and 3 (0.2%) ( Figure 3 ). Similar results were seen when evaluating NT-proBNP according to deciles or an established dichotomous cut point (see online-only Data Supplement Figure III ). The addition of the highest quartile of baseline NT-proBNP to the risk factors of history of heart failure and eGFR further stratified patients according to baseline risk of hospitalization for heart failure regardless of treatment assignment (see online-only Data Supplement Figure IV ). The addition of the NT-proBNP to the 2 clinical variables increased the c-statistic from 0.74 to 0.82 (P<0.001). Among the lowest quartiles of NT-proBNP, most patients had none of the aforementioned risk factors for heart failure (n=6599, 53.6%), a correspondingly low rate of heart failure, and no treatment difference between saxagliptin or placebo (0.6% versus 0.6%; HR, 0.84; 95% CI, 0.46-1.52; P=0.56), whereas in patients with NT-proBNP in the top quartile and 2 risk factors, the absolute risk difference was 1.6% (see online-only Data Supplement Figure V ). The baseline concentration of NT-proBNP was a particularly strong risk factor for hospitalization for heart failure. Even among patients with normal renal function and no reported history of heart failure, a level of NT-proBNP in quartile 4 (>332 pg/mL) was associated with a higher risk of hospitalization for heart failure (4.3% versus 0.6% with lower levels of NT-proBNP; see online-only Data Supplement Figure IV ) and a correspondingly higher absolute risk with saxagliptin compared with placebo (5.35% versus 3.33%; P=0.083; see online-only Data Supplement Figure V ).
Change in NT-proBNP, High-Sensitivity Troponin T, and C-Reactive Protein
In patients with both baseline and 2 years or end-oftreatment assessments, median NT-proBNP (n=2026) Hazard ratio, CI and P value for risk of event for subjects with characteristic relative to base category. Data on race/ethnicity were entered by study coordinators based on patient self-identification. ACE indicates angiotensin converting enzyme; CI, confidence interval; HR, hazard ratio; and IQR, interquartile range.
*Per unit of measurement defined in the 1st column. †HR per 10 U increase for fasting glucose and eGFR. ‡HR per 1 U increase for log albumin:creatinine ration. 
Patients with Previous Heart Failure
A total of 2105 patients (12.8%) reported previous heart failure at baseline. They were older and more likely to have established cardiovascular disease and renal impairment, although there was no difference in the duration of DM and only a small difference in baseline hemoglobin A1c (7.7% in previous heart failure versus 7.6% in no previous heart failure; P=0.08).
More patients with previous heart failure were on aspirin, statins, β-blockers, and insulin, but fewer were on metformin or sulfonylureas (see online-only Data Supplement Table III) . Patients with previous heart failure were at increased risk of all cardiovascular events compared with those without previous heart failure. The relative effect of saxagliptin versus placebo was similar in patients with and without previous heart failure for the primary and secondary composite end points, as well as all-cause mortality. However, the absolute increase in the rate of hospitalization for heart failure with saxagliptin was 1.5% in patients with previous heart failure compared with 0.6% in patients without previous heart failure (P for interaction=0.67). The rates of cardiovascular events, as well as hypoglycemia, and adverse events are presented in the online-only Data Supplement Table IV . We further evaluated the risk of hospitalization for heart failure in patients with previous heart failure by New York Heart Association Functional Classification (see online-only Data Supplement Table V) . Similar to the overall trial, the primary and secondary endpoints were balanced between treatment arms in patients with higher NHYA classification (Data not shown).
Discussion
In patients with established cardiovascular disease or multiple cardiovascular risk factors, the DPP-4 inhibitor saxagliptin, when compared with placebo, increased the risk of hospitalization for heart failure, in particular during the first 12 months of therapy. Several clinical features easily identified patients at highest absolute risk of heart failure, regardless of treatment assignment. Although there were no individual predefined subgroups in which the relative risk associated with saxagliptin treatment was particularly high or low, the incremental risk with saxagliptin was greatest in patients at a high overall risk of heart failure (ie, history of heart failure, impaired renal function, or elevated baseline levels of NT-proBNP) and correspondingly small in patients at lower risk. Therefore, a combination of clinical factors and biomarkers identify a population of patients with DM in whom the excess risk of hospitalization for heart failure with saxagliptin treatment is greatest, while Figure 2 . Risk of hospitalization for heart failure with saxagliptin or placebo in patients with and without baseline risk factors (eGFR <60 mL/ min or history of previous heart failure). ARD indicates absolute risk difference; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; KM, Kaplan-Meier; and # excess HHR events/1000 pt-years, the number of excess hospitalizations for heart failure in patients treated with saxagliptin versus placebo per 1000 patient-years. conversely identifying a larger population without those features in whom the absolute risk is small. Based on the mechanism of action of saxagliptin and the accumulated preclinical and clinical data of DPP-4 antagonists, the observation of a higher incidence of hospitalization for heart failure in patients treated with saxagliptin in the SAVOR-TIMI 53 trial was unexpected and requires confirmation with several ongoing cardiovascular outcomes trials of DPP-4 inhibitors and glucagon-like peptide-1 agonists. 26, 27 There was no signal of fluid retention, weight gain, or heart failure with saxagliptin in the Phase 2 and Phase 3 development program. 28 Moreover, previous preclinical data and small studies with other incretin-based agents suggested potential improvement of left ventricular function, 26 but these data are inconsistent. Two preliminary reports of other studies in patients with DDP-4 inhibitors produced unanticipated findings that highlight potential mechanisms by which treatment with DPP-4 inhibitors could exacerbate heart failure. In 1 study in patients with reduced left ventricular function, after 12 months of therapy, the DPP-4 inhibitor vildagliptin increased left ventricular end diastolic volumes. 27 In another 6-week trial, several DPP-4 inhibitors worsened endothelial function as assessed by flow-mediated dilation, independent of glucagon-like peptide-1 levels or DPP-4 activity. 29 Regardless, no clear mechanism of action to explain the increased risk of hospitalization for heart failure in the SAVOR-TIMI 53 trial could be identified.
Although unexpected, the incremental risk of heart failure hospitalization observed with saxagliptin is likely valid, given the large number of events and the prespecification of heart failure hospitalizations as a component of the secondary end point, together with central blinded adjudication. However, the observation of an increased risk of hospitalization for heart failure with saxagliptin must be taken in the context of multiple testing and the risk of a "false-positive" result, although there was a statistically significant difference between the 2 groups after post hoc adjustment for multiple comparisons. Left ventricular function was not captured at baseline, and therefore the temporal changes, even in patients with previous heart failure, cannot be evaluated.
The 
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When the 712 first hospitalization for heart failure events from both studies are combined, the overall odds of hospitalization for heart failure with DPP-4 inhibition is 1.24 (95% CI, 1.07-1.44; P=0.004; see online-only Data Supplement Figure VI ).
An increased risk of heart failure has been observed in some studies of other antihyperglycemic agents, including sulfonylureas, 13 thiazolidinediones, [7] [8] [9] 11 and dual peroxisome proliferator-activated receptor α/γ agonists, 10, 31 with divergent results in trials of intensive glucose management. 32, 33 The lack of adequate safety data on antihyperglycemic agents in heart failure is highlighted by the example of metformin, which for many years was contraindicated in patients with heart failure, until observational data demonstrated an acceptable safety profile. 15, 16 Patients with both DM and heart failure are relatively under-represented in clinical trials that either excluded them [34] [35] [36] or enrolled <5% of the population. 37, 38 Therefore, the 2105 patients with previous heart failure in the SAVOR-TIMI 53 trial represent 1 of the largest cohorts of such patients with DM studied. 1 There are presently no known mechanisms by which DPP-4 inhibition could precipitate heart failure. The hemodynamic effects of glycemic modulation in myocardium accustomed to years of hyperglycemia are unknown and could potentially exacerbate cardiac dysfunction because glycemic changes may unfavorably alter the balance of free fatty acid oxidation and glycolysis. 39 Intensive glycemic control increased the risk of heart failure in 1 of the large glucose-lowering trials 40 but not in 2 others. 36, 38 In contrast to the thiazolidinediones, there is no signal of volume overload observed in the SAVOR-TIMI 53 trial with saxagliptin, nor did saxagliptin raise levels of NT-proBNP. However, interestingly, treatment with the glitazones increases levels of natriuretic peptides in some studies 41 but not all studies. 7 The cardiovascular consequences of DPP-4 inhibition on other peptide substrates, such as natriuretic peptides or bradykinins, are also unknown, nor was there evidence of direct myocardial toxicity with saxagliptin as reflected by the similar change in concentrations of high-sensitivity troponin T and high-sensitivity C-reactive protein between treatment groups.
With the possible exception of metformin 15, 16 and insulin, 42 most reported studies to date evaluating effects on heart failure of specific glucose-lowering medications either increased the risk of heart failure or were insufficiently powered and therefore often discordant. 33 Moreover, the trials of metformin and insulin by design enrolled patients with recently diagnosed DM in whom glycemic modulation may be better tolerated by the myocardium. In this wellpowered study of patients at high cardiovascular risk, we found that saxagliptin did not increase the overall risk of the primary or secondary cardiovascular composite end points, even in those with previous heart failure. However, patients treated with saxagliptin had an increased risk of hospitalization for heart failure-an event that itself was associated with a high subsequent mortality-and in particular in patients at the highest absolute risk of heart failure. The decision to choose 1 antihyperglycemic agent versus another must balance the benefit in reducing microvascular complications via improved glycemic control together with potential adverse events, such as hypoglycemia and heart failure. The results from contemporary large cardiovascular outcome studies in patients with DM across the spectrum of classes of antihyperglycemic agents will greatly improve our evidence-based approach to treatment of these 2 commonly coexistent conditions. 
Sources of Funding
CLINICAL PERSPECTIVE
Diabetes mellitus and heart failure frequently coexist. However, few diabetes mellitus trials have prospectively evaluated and adjudicated heart failure as an end point. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial randomized 16 492 patients with diabetes mellitus to either saxagliptin or placebo. There were no differences between groups in relation to the risk of the primary and secondary composite end points or overall mortality, but there was a 0.8% absolute and 27% relative increased risk of hospitalization for heart failure in patients treated with saxagliptin. The increased risk appeared to be confined to the first 12 months of treatment. Several clinical features, such as history of previous heart failure, estimated glomerular filtration rate <60 mL/min, and an elevated level of N-terminal pro B-type natriuretic peptide, identified those patients at overall highest risk of hospitalization for heart failure in whom the absolute risk with saxagliptin was highest. Conversely, patients without these risk factors were at low risk of hospitalization for heart failure, and the associated additional risk with saxagliptin was minimal. There is no known mechanism by which saxagliptin, or dipeptidyl peptidase-4 inhibitors in general, could exacerbate heart failure, and in this cohort, saxagliptin did not increase levels of N-terminal pro B-type natriuretic peptide, high-sensitivity troponin T, or high-sensitivity C-reactive protein compared with placebo. Other ongoing studies of other incretin-based therapies will further clarify whether this was a "chance" observation or a true side effect. Regardless, the SAVOR-TIMI 53 trial met the primary safety objective demonstrating no increased risk of cardiovascular death, myocardial infarction, or ischemic stroke with saxagliptin. These data provide additional information when considering newer antihyperglycemic agents in patients at high risk of cardiovascular events.
Correction e198
In the article by Scirica et al, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial," which appeared in the October 28, 2014 issue of the journal (Circulation. 2014; 130:1579 -1588 . doi:10.1161/CIRCULATIONAHA.114.010389), the authors discovered an error in the original coding that incorrectly calculated the number of excess hospitalization for heart failure events per 1000 patients treated with saxagliptin. The incorrect data are presented in portions of Figures 2, 3 , Supplemental Figure V , and in 1 sentence in the Results section. Despite the changes to these numbers, there were no qualitative differences based on the updated results. Therefore, the discussion and conclusions remain valid and have not been amended. The authors apologize for this error. Figure 3 . Risk of hospitalization for heart failure with saxagliptin or placebo according to baseline quartile of NT-proBNP (picograms per milliliter). ARD indicates absolute risk difference; HR, hazard ratio; NT-proBNP, N-terminal pro B-type natriuretic peptide; Q, quartile; and # excess HHR events/1000 pt-years, the number of excess hospitalizations for heart failure in patients treated with saxagliptin versus placebo per 1000 patient-years. Figure 2 . Risk of hospitalization for heart failure with saxagliptin or placebo in patients with and without baseline risk factors (eGFR <60 mL/min or history of previous heart failure). ARD indicates absolute risk difference; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; KM, KaplanMeier; and # excess HHR events/1000 pt-years, the number of excess hospitalizations for heart failure in patients treated with saxagliptin versus placebo per 1000 patient-years. To test for a differential relationship between saxagliptin and hospitalization for heart failure by time after randomization, we created a time-varying interaction term (treatment*time) and found the p value for interaction= 0.017, suggesting heterogeneity. To further examine the attenuating effects of saxagliptin on the risk of hospitalization due to heart failure, a time varying coefficients model over 10 time intervals where the number of events are equally distributed was developed. The figure represents this analysis.
The lower confidence interval of the log HR crosses 0 at around 314 days, suggesting that about 10-11 months is when the risk of hospitalization for heart failure with saxagliptin subsided in this trial.
Supplemental Figure 2
The Risk of Hospitalization for Heart Failure according to Treatment with Saxagliptin versus Placebo in Various Subgroups.
Supplemental Figure 3
The Risk of Hospitalization for Heart Failure by Deciles (top) and Established Cutpoint (bottom). The risk of hospitalization for heart failure is low in the lower levels of NT-proBNP but the risk associated with saxagliptin is present at all levels of NT-proBNP. We have repeated our analysis using a cutpoint of 125 pg/mL for patients younger than 75 years and 450 pg/mL for patients 75 years or older which is listed in the product insert for this assay and is based on data from an elderly cohort with stable coronary artery disease, where the top quartile of NT-proBNP was > 450 pg/ml.
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In another cohort of patients with T2DM, in whom the majority did not have established coronary disease, the highest quartile was 200 pg/ml. 
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Supplemental Figure 4
Increased Risk of Hospitalization for Heart Failure in patients according to Baseline Quartiles of NTproBNP and Number of Baseline Risk Factors (eGFR < 60 mL/min or prior history of heart failure). ARD -Absolute risk difference; HR -hazard ratio; # excess events per 1000 pt-years refers to the number of excess hospitalizations for heart failure in patients treated with saxagliptin versus placebo per 1000 patients-years.
Supplemental Figure 5
Risk of Hospitalization for Heart Failure with Saxagliptin or Placebo in Patients with Normal and Elevated concentrations of NT-proBNP according to Baseline Risk Factors (eGFR < 60 ml/min or prior history of heart failure). ARD -Absolute risk difference; HR -hazard ratio; # excess events per 1000 ptyears refers to the number of excess hospitalizations for heart failure in patients treated with saxagliptin versus placebo per 1000 patient-years.
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Supplemental Figure 6 Pooled Analysis of the Risk for Hospitalization for Heart Failure from the SAVOR-TIMI 53 and EXAMINE Trials in patients treated with a DPP4 inhibitor.
Methods:
The measure of effectiveness of DDP-IV inhibitors on hospitalization due to heart failure (HHF) from individual trial is summarized as odds ratios using observed and expected number of events. These individual odds ratios were then combined by Peto method (Yusuf et al. 1985) to yield a point estimate of the pooled effect and 95% confidence interval. The pooled effect describes a weighted average of the studies, giving more weight to a larger sized trial. Statistical heterogeneity across the two trials was assessed by Cochran's Q statistic.
This figure presents a meta-analysis of the effects of DDP-IV inhibitors (alogliptin and saxagliptin) on hospitalization due to heart failure (HHF) endpoint from two recently completed randomized clinical trials. The number of HHF events is given in the left two columns for treatment and placebo groups, respectively. The treatment and control group sizes were comparable in each trial (8280 vs 8212 in SAVOR; 2701 vs 2679 in EXAMINE trial 26 ). There was no statistical heterogeneity across these two trials (Cochran's Q=0.13 with df=1, p-value=0.714). Therefore, results are summarized from the fixed effects estimates only. The pooled estimate of Peto odds ratios indicates there is a 24% increase in risk of admission to hospital due to heart failure in DPP IV inhibitor treatment group (odds ratio 1.24; 95% CI 1.07-1.44). Nonetheless, these results should be interpreted with a caution as the combined estimate is based upon only two trials. 1.17 (0.91, 1.51) 1.39 (1.09, 1.77 
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